Cefprozil Anhydrous, (E)-

Summary

Cefprozil Anhydrous, (E)- (CHEMBL276568) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 389.4 Da · C18H19N3O5S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL276568
Name	Cefprozil Anhydrous, (E)-
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5281006
Molecular formula	C18H19N3O5S
Molecular weight	389.4
InChIKey	WDLWHQDACQUCJR-ZAMMOSSLSA-N

SMILES: C/C=C/C1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)SC1)C(=O)O

IUPAC name: (6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(E)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

Parent form; salt/anhydrous children: CHEMBL5314373

Patent coverage: 65 distinct patent families (191 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).